Pliant Therapeutics Inc
Research Pliant Therapeutics Inc (PLRX) on Bullrun: market cap USD 73.69M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPLRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 73.69M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 113.22M
- Free cash flow-USD 19.23M
Valuation Snapshot
latest market cap is USD 73.69M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | USD 149.30M | -USD 128.71M | n/a | -2.43 | USD 45.45M | USD 0 | USD 181.21M |
| FY2024 | USD 0 | USD 210.30M | -USD 159.35M | n/a | -3.47 | USD 71.19M | USD 30.21M | USD 304.08M |
| FY2023 | USD 1.58M | USD 161.30M | -USD 117.28M | n/a | -2.75 | USD 63.23M | USD 10.05M | USD 473.58M |
| FY2022 | USD 9.69M | -USD 123.32M | -USD 96.39M | n/a | -2.94 | USD 33.69M | USD 9.93M | USD 313.34M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 73.69M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 74.97M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 801.54M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.08B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 942.52M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 487.12M | n/a | n/a | n/a |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pliant Therapeutics Inc's market cap?
Pliant Therapeutics Inc's market capitalization is USD 73.69M.
What does Pliant Therapeutics Inc do?
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc.